Assembly biosciences presents new data highlighting herpes simplex virus development candidate abi-5366 at the 47th annual international herpesvirus workshop

-- first presentation of preclinical data describing the activity, pharmacokinetics and safety profile of abi-5366, supporting planned clinical entry in 1h 2024 -- south san francisco, calif., july 17, 2023 (globe newswire) -- assembly biosciences, inc. (nasdaq: asmb), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced data from development candidate abi-5366, a long-acting herpes simplex virus (hsv) helicase inhibitor targeting high-recurrence genital herpes, featured in one oral and one poster presentation at the 47th annual international herpesvirus workshop in missoula, montana, taking place july 15-19, 2023.
ASMB Ratings Summary
ASMB Quant Ranking